Legend Biotech Tanks 11% — Dead Money or J&J’s Perfect Acquisition Target?
Legend Biotech's stock fell 11% to a new 52-week low after missing sales expectations for its cancer drug, Carvykti. Despite analyst price target reductions, management is sticking to its forecast. This episode examines whether the stock decline presents a value trap or a…